Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01891344 · ClinicalTrials.gov registry record · Phase 2
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
A Phase 2 study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by pharmaand.
- Completed
- Registry status
- Phase 2
- Development phase
- 491
- Enrollment target
- 20
- Study locations
NCT01891344: Completed Phase 2 study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by pharmaand.
NCT01891344 is a Phase 2 study of Ovarian Cancer and Fallopian Tube Cancer that has completed, run by pharmaand. The registered enrollment target is 491 participants, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (32% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01891344, a Phase 2 study of Ovarian Cancer and Fallopian Tube Cancer, has completed, sponsored by pharmaand.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 491 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine which patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib.
Primary Outcome
The primary efficacy endpoint of PFS is calculated as 1+ the number of days from the first dose of study drug to disease progression by RECIST (Response Evaluation Criteria in Solid Tumors), as determined by the investigator or death due to any cause, whichever occurs first. Progression is defined using RECIST v1.1, as at least a 20% increase in the sum of the longest diameter of target lesions, or a measureable increase in a non-target lesion, or the appearance of new lesions.
Conditions Studied
Interventions
- DRUG Oral rucaparib
Study Locations (20)
California
- Saint Jude Heritage Medical Center - Fullerton
- University of California Los Angeles - Los Angeles
- UC San Diego - San Diego
- California Pacific Medical Center - San Francisco
- University of California, San Francisco - San Francisco
- Coastal Integrative Cancer Care - San Luis Obispo
- Central Coast Medical Oncology - Santa Maria
- Stanford University - Stanford
Florida
- Mayo Clinic Jacksonville - Jacksonville
- Altus Research - Lake Worth
- University of Miami Hospital & Clinics Sylvester Comprehensive Cancer Center - Miami
- Florida Hospital Cancer Institute - Orlando
- UF Health Cancer Center - Orlando
Alaska
- Providence Alaska Medical Center - Anchorage
Arizona
- University of Arizona Cancer Center - Tucson
Colorado
- Rocky Mountain Cancer Centers - Lakewood
Indiana
- Horizon BioAdvance - Lafayette
Kentucky
- Norton Cancer Institute - Louisville
Maryland
- Johns Hopkins Kimmel Cancer Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 491 participants |
| Start Date | 2013-10-30 |
| Est. Completion | 2021-09-28 |
| Phase | Phase 2 |
What the finished NCT01891344 record still lists
NCT01891344 is an interventional study that assigns participants to a tested intervention. The registered 491 participants enrollment target is mid-sized for trials with a published cap, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (32% lower).
The record links to 4 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which Oral rucaparib is the first listed.
NCT01891344 names 20 study sites across 9 states, led by California, Florida, Alaska.
Frequently Asked Questions
What is clinical trial NCT01891344 about?
NCT01891344 is a clinical study titled "A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)". The purpose of this study is to determine which patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib.
What is the current status of trial NCT01891344?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 491 participants. The study started on 2013-10-30. Estimated completion is 2021-09-28.
What conditions does trial NCT01891344 study?
This clinical trial studies the following conditions: Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Peritoneal Cancer.
What interventions are being tested in trial NCT01891344?
The interventions under investigation include: Oral rucaparib (DRUG).
Who is sponsoring clinical trial NCT01891344?
This trial is sponsored by pharmaand, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01891344 being conducted?
This trial has 20 study locations across Alaska, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01891344's enrollment target sits among peer trials
491 51st of 322 higher than 272 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03418961 · 491 participants · Phase 3
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- NCT05861973 · 492 participants · NA
SMARTer Weight Loss Management
- NCT05908331 · 492 participants · NA
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
- NCT06152575 · 492 participants · Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI